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Background: Human thioredoxin is a 12 kDa cellular
redox protein that plays a key role in maintaining the
redox environment of the cell. It has recently been shown
to be responsible for activating the DNA-binding proper-
ties of the cellular transcription factor, NFKB, by reducing
a disulfide bond involving Cys62 of the p50 subunit.
Using multidimensional heteronuclear-edited and hetero-
nuclear-filtered NMR spectroscopy, we have solved the
solution structure of a complex of human thioredoxin
and a 13-residue peptide extending from residues 56-68
of p50, representing a kinetically stable mixed disulfide
intermnnediate along the reaction pathway.
Results: The NFKB peptide is located in a long boot-
shaped cleft on the surface of human thioredoxin
delineated by the active-site loop, helices oa2, c03 and at4,
and strands 3 and 4. The peptide adopts a crescent-
like conformation with a smooth 1100 bend centered
around residue 60 which permits it to follow the path of
the cleft.
Conclusions: In addition to the intermolecular disulfide
bridge between Cys32 of human thioredoxin and Cys62
of the peptide, the complex is stabilized by numerous
hydrogen-bonding, electrostatic and hydrophobic inter-
actions which involve residues 57-65 of the NFKB pep-
tide and confer substrate specificity. These structural
features permit one to suggest the specificity requirements
for human thioredoxin-catalyzed disulfide bond reduction
of proteins.
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Introduction
A growing body of evidence over recent years has
demonstrated that the DNA-binding properties of a
number of eukaryotic transcription factors are regulated
by a thiol-redox control mechanism involving the reduc-
tion of a specific cysteine residue [1-9]. The best studied
examples include, NFKB, AP-1, TFIIIC, BZLF1 and
Myb. In the case of NFKB, it has been shown both in
vitro and in vivo that human thioredoxin (hTRX), a
12 kDa cellular redox protein, is responsible for the acti-
vation of its DNA-binding properties by specifically
reducing a disulfide bond involving a critical cysteine
residue at position 62 of the p50 subunit [1-3].
Thioredoxins are found in many organisms ranging from
prokaryotes to eukaryotes and play a key role in main-
taining the redox environment of the cell [10], acting as
potent reducing agents for disulfide bonds in many pro-
teins [11]. A human protein with thioredoxin-like activ-
ity was first identified in human platelet extracts [12] and
subsequently shown to be present in human cultured
fibroblasts [13]. Approximately 10 years later, hTRX was
identified independently as a highly expressed cytokine-
like factor in activated T and B cell lines that induced the
production of the interleukin-2 receptor a chain and
interleukin-2 [14-20], both of which are under the
transcriptional control of NFKB [21].
NFKB is an important cellular transcription factor
[22-25] that regulates not only a wide variety of cellular
genes, particularly those involved in host defense, but also
a number of viral genes including those of the proviral
form of HIV-1 [26,27]. We have therefore undertaken a
structural study to investigate the molecular basis of the
hTRX-mediated activation of NFKB. To this end we
have determined the solution structure of a disulfide-
bonded complex between hTRX and a 13-residue pep-
tide comprising residues 56-68 of the p50 subunit of
NFKB and encompassing Cys62. This portion of NFKB,
which is located in the L1 loop, makes numerous con-
tacts to DNA in the crystal structure of the NFKB p50
homodimer bound to a KB site [28,29]. The structure of
the hTRX-NFkB peptide complex also represents the
first structure of a mixed disulfide intermediate on the
reaction pathway involving thioredoxin from any species
and thus sheds light on the specificity of thioredoxin-
catalyzed disulfide bond reduction.
Results and discussion
Structure determination
The proposed mechanism of disulfide bond reduction by
thioredoxin involves nucleophilic attack by the highly
reactive Cys32 thiolate anion (pKa -6.3 in hTRX [30])
of the reduced species on a disulfide-containing substrate,
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producing a mixed disulfide intermediate (that is, an
intermediate containing an intermolecular disulfide
bond), followed by attack of the thiolate of Cys35 (pKa
-7.5-8.6 in hTRX [30]) to yield a reduced substrate and
oxidized thioredoxin [31]. We therefore trapped a kineti-
cally stable mixed disulfide intermediate (that is an inter-
mediate containing an intermolecular disulfide bond) of
hTRX and the NFKB peptide using the quadruple
Cys--Ala mutant (C35A, C62A, C69A and C73A) of
hTRX which retains the reactive Cys32. The mutations
Cys62--Ala, Cys69-Ala and Cys73--Ala were previ-
ously introduced into the protein in our study of the
structures of reduced and oxidized hTRX to circumvent
any problems arising from intermolecular disulfide bond
formation involving the three free non-active-site cys-
teine residues (Cys62, Cys69 and Cys73) upon oxidation
[32]. The mixed disulfide intermediate was formed by
reacting the mutated hTRX with the NFKB peptide at
pH 8, and purified by high-performance liquid chro-
matography (HPLC). A similar strategy was employed to
determine the structure of a mixed disulfide intermediate
of glutaredoxin and glutathione [33,34].
The structure was solved by means of multidimensional
double and triple resonance heteronuclear-filtered and
heteronuclear-edited NMR spectroscopy making use
of the NFKB peptide at natural isotopic abundance (i.e.
12C and 14N), and uniformly (>95%) 15N and
15 N/13C-labeled hTRX. An example of the quality of
the data is shown in Fig. 1 which illustrates strips taken
from the three-dimensional (3D) 13 C edited(F2)/1 2 C(F3 )-
filtered nuclear Overhauser enhancement (NOE) spec-
trum illustrating short interproton distance contacts
specifically between 13C-attached protons of hTRX and
12C-attached protons of the unlabeled NFKB peptide.
The structural statistics for the final ensemble of 60 simu-
lated annealing structures, calculated on the basis of 3169
experimental NMR restraints, are summarized in Table 1,
and a stereoview of a best fit superposition of the back-
bone atoms and ordered side chains is shown in Fig. 2.
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The restraints comprise 2582 approximate distance
restraints as follows: 2357 intramolecular hTRX inter-
proton distance restraints [subdivided into 690 intra-
residue restraints, and 503 sequential ( i-j =l), 437
short-range (1< i-j <5) and 727 long-range (li-jl>5)
inter-residue restraints], 115 intramolecular NFKB
peptide interproton distance restraints (subdivided into
64 intra-residue restraints and 38 sequential and 13
medium-range inter-residue restraints), 74 intermolecu-
lar hTRX-NFKB interproton distance restraints, and 36
distance restraints for 18 hydrogen bonds in hTRX.
These were supplemented by 300 torsion angle restraints
(104 , 76 /, 78 X1 and 31 X2 restraints for hTRX, and
7 X1 and 4 X2 restraints for the NFKB peptide), 88 3JHNa
coupling constant restraints, and 102 13Cot and 97 13C3
chemical shift restraints. The N-terminal (residue 56) and
C-terminal (residue 68) residues of the NFKB peptide,
which are not in contact with hTRX, are disordered.
The remainder of the complex is very well defined with
a precision [defined as the average root mean square
(rms) difference between the individual simulated anneal-
ing structures and the mean coordinate positions] of
0.21+0.02 A for the backbone atoms, 0.57-0.03 A for all
atoms and 0.34+0.03 A for all ordered atoms (Table 2).
Description of the structure
The overall structure of hTRX in the complex is similar
to that of oxidized and reduced hTRX [32] and is char-
acterized by a five-stranded 3-sheet (residues 1-5, 22-28,
53-59, 75-81 and 84-91) arranged in a -2x, +ix, -2, -1
topology [35] and surrounded by four ox-helices (residues
7-17, 33-49, 62-70 and 94-105). The backbone atomic
rms difference between the mean coordinates of the
hTRX-NFKB complex and oxidized hTRX, the
hTRX-NFKB complex and reduced hTRX, and re-
duced and oxidized hTRX are 0.64 A, 0.83 A and
0.86 A, and the corresponding values for all atoms are
0.78 A, 1.0 A and 1.0 A, respectively. As the precision of
the solution structures of reduced and oxidized hTRX
[32] is comparable to that of the complex reported here,
Fig. 1. Composite of 13C-H strips taken
from the 120 ms mixing time 600 MHz
3D 13C(F2)-edited/ 12C(F3)-filtered NOE
spectrum of the hTRX-NFKB peptide
complex, illustrating NOEs between
protons of the unlabeled peptide
(attached to 12C along the F3 axis) and
protons of labeled hTRX (attached to
13C). Residues of hTRX and the NFKB
peptide are indicated by upper-case and
lower-case letters, respectively.
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Table 1. Structural statistics.a
<SA> (SA),
Rmsds from experimental
distance restraints (A)b
All (2582) 0.026+0.001 0.026
Intramolecular hTRX interproton distances
inter-residue sequential (i-j(= =1) (503) 0.018+0.003 0.016
inter-residue short range (1 <i-j <5) (437) 0.034+0.003 0.039
inter-residue long range (i-j|>5) (727) 0.027±0.002 0.029
intra-residue (690) 0.019+0.001 0.014
Intramolecular NFKB peptide
interproton distances (11 5) 0.032 ±0.003 0.032
Intermolecular hTRX-NFKB
interproton distances (74) 0.053+0.006 0.054
hTRX hydrogen-bond restraints (36) 0.024 0.007 0.026
Rmsds from complete cross-validated
experimental distances (A)C 0.15 ±0.06
Rmsds from 3JHNc, coupling
constants (Hz) (88)b 0.41 ± 0.03 0.47
Rmsds from experimental
dihedral restraints () (300) b 0.38+ ±0.05 0.50
Rmsds from experimental
secondary shifts (ppm)
13Ca (102) 1.02 0.02 1.07
T3CP (97) 1.10±0.02 1.12
Deviations from idealized covalent geometry
Bonds (A) (1865) 0.004± 0.0003 0.005
Angles (') (3360) 0.594±0.014 0.658
Impropers () (969)d 0.407+0.028 0.531
EL_j (kcal mol - 1)e -576± 10 -561
aThe notation of the NMR structures is as follows: <SA> are the final 60 simu-
lated annealing structures; SA is the mean structure obtained by averaging the
coordinates of the individual SA structures best fitted to each other (excluding
residues 56 and 68 of the NFKB peptide); (SA), is the restrained minimized
mean structure obtained by restrained regularization of the mean structure
SA. The number of terms for the various restraints is given in parentheses
and applies to the entire complex. bNone of the structures exhibits distance
violations >0.3 A, dihedral angle violations >5 °, or 3JHN coupling constant
violations >2 Hz; and there are no systematic interproton distance violations
between 0.1 A and 0.3 A among the ensemble of calculated structures. For
each backbone hydrogen bond there are two distance restraints: rNHO, 1.7-
2.5 A; rNO, 2.3-3.5 A. cThe value quoted represents the average rmsd for all
test sets which comprise a different subset (10%) of the data in each calcula-
tion. dThe improper torsion restraints serve to maintain planarity and chirality.
All peptide bonds were constrained to be planar and trans with the exception
of the peptide bond between Thr74 and Pro75 which is in the cis conforma-
tion [32]. eEL_J is the Lennard-Jones van der Waals energy calculated with
the CHARMM 181] empirical energy function and is not included in the tar-
get function for simulated annealing or restrained minimization.
the differences between the structures, albeit small, are
significant. Thus, the overall structure of hTRX in the
complex is slightly closer to that of the oxidized species
than to that of reduced hTRX.
To facilitate discussion, we denote the residue numbering
of the NFKB peptide as follows: So represents the disul-
fide-bonded cysteine, and negative and positive numbers
indicate residues N-terminal and C-terminal to this cys-
teine, respectively. Residues S_5(Arg57) to S+3 (Pro65) are
in contact with hTRX. They bind in a crescent-like
conformation to a boot-shaped cleft on the surface of
hTRX, which is 8-10 A wide and 5-6 A deep, with the
shank and foot of the boot -18 A and 15 A in length,
respectively (Fig. 3). The angle between the long axes of
the boot and shank is ~110° . In the views shown in
Figs 3 and 4a, the borders of the cleft are formed by the
N terminus of helix ot2 and the C terminus of helix oa4
(located at the top of hTRX), the active-site loop
(residues 31-36) and the C terminus of strand 33 (on the
left-hand side), and by helix x3, the loop connecting
helix cx3 and strand 134, and strand 135 (on the right-hand
side). Residues S_5(Arg57)-S_ 3(Arg59) are located in the
foot of the cleft, with residues S_2 (Tyr60)-S+ 3(Pro65)
located in the shank. The side chain of the S 3(Arg59)
residue points directly into the heel of the cleft. The
chain of the NFKB peptide follows the cleft by bending
smoothly through 1100 with the bend centered on the
S_2(Tyr60) residue. The S 3(Pro65) residue abuts the
uppermost point of the cleft where the cleft boundaries
force the chain of the NFKB peptide to reverse direction
resulting in a turn centered on residues S+3 (Pro65) and
S+4(Ser66). This turn is accompanied by a backbone car-
bonyl to amide hydrogen bond between the S+ 2(Gly64)
and S+5(His67) residues. The polypeptide backbone of
the NFKB peptide is defined up to the Ccx carbon of
the S+5 residue; the side chain of this residue makes no
contact with hTRX and is disordered.
The disulfide bridge between Cys32 of hTRX and
So(Cys62) has a right-handed trans-trans-gauche(+)-trans-
gauche(-) conformation with a C-Cx separation of
6.8 A, similar to that of the disulfides that span the
3-barrels in immunoglobulins [35]. In addition to the
covalent linkage afforded by the disulfide bridge, the
complex between the NFKB peptide and hTRX is stabi-
lized by numerous non-covalent interactions that confer
specificity to substrate binding. These are illustrated in
detail in Fig. 4.
There are three backbone hydrogen bonds between the
NFKB peptide and hTRX in the immediate vicinity of
the S(Cys62) residue. In particular, the backbone car-
bonyl of the S_2(Tyr60) residue is hydrogen bonded to
the backbone amide of Thr74, and the backbone amide
and carbonyl of the S+l(Glu63) residue are hydrogen
bonded to the backbone carbonyl of Thr74 and the back-
bone amide of Ala92, respectively. There are five electro-
static interactions involving three side chains of the NFKB
peptide. The guanidinium group of the S5(Arg57)
residue forms a salt bridge with the side-chain carboxy-
lates of Asp58 and Asp61l; the guanidinium group of the
S_3(Arg59) residue is hydrogen bonded to the side-chain
carbonyl of Gln63 and the hydroxyl group of Ser67; and
the carboxylate of the S+1 (Glu63) residue forms a hydro-
gen bond with the hydroxyl group of Ser9O). It should be
noted that, on the basis of pH titration data UQ, GMC
and AMG, unpublished data), the carboxylate groups of
Asp58 and Asp61 are negatively charged at the pH of 4.4
employed in this study. In addition, it seems likely that
the hydroxyl group of the S_2(Tyr6O) residue is hydrogen
bonded to the backbone carbonyl of Phe27 via a bridg-
ing water molecule. Finally, an extensive set of hydro-
phobic interactions is observed. The aromatic ring of the
S_4(Phe58) residue is stacked against the six-membered
ring of Trp31; the aliphatic portion of the side chain of
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Fig. 2. Stereoview showing a best fit
superposition of the backbone N, Ca, C
atoms and ordered side chains of the 60
simulated nnealing structures of the
hTRX-NFKB complex. The backbone
and side chains of hTRX are shown in
red and blue, respectively; the back-
bone and side chains of the NFKB pep-
tide are shown in green and pink,
respectively, and the disulfide bond
between Cys32 of hTRX and Cys62 of
the NFKB peptide is shown in yellow. P
designates a residue from the NFKB
peptide. (Figure generated with the
program AVS-X-PLOR [821.)
the S 3 (Arg59) residue is in contact with the methyl
groups of Val59 and Ala66; the aromatic ring of the
S_ 2(Tyr6O) residue is in contact with the methyl groups of
Val59, Ala66, Val71 and Thr74; the 3-methine of the
S_1(Val61) residue and the 13- and y-methylene groups of
the Sl 1(Glu63) residue are in contact with Ala73; the
disulfide bridge involving the So(Cys62) residue is in con-
tact with the methyl group of Ala35 and the side chains
of Pro34 and Pro75; the S 2 (Gly64) residue is in contact
with Pro34; and finally, the S+5 (Pro65) residue is in con-
tact with Pro34, the C-methyl and Cy-methylene
groups of Ile38, the C13- and Cy-methylene groups of
Met37, and the methyl group of Ala92. It is worth noting
that the variant of hTRX employed in this study has a
threonine at position 74 [36], whereas another variant has
a methionine at this position [18]. This difference should
have no effect on the hydrophobic interaction between
the residue at position 74 and the aromatic ring of the
S_2 (Tyr60) residue of the peptide.
The importance of these hydrophobic interactions can be
ascertained by calculating the solvation free energy (SFE)
of folding [37] of the complex relative to its individual
components. Formation of the complex is associated
with a decrease of 768 A2 and 535 2 in the solvent
accessible surface area of the NFKB peptide and hTRX,
Fig. 3. View of the molecular surface of hTRX illustrating the cleft
in which the NFKB peptide is located. The degree of curvature of
the molecular surface is color coded from white (convex) to dark
gray (concave). Hence the cleft is visualized as the contiguous
boot-shaped gray region on the surface of hTRX. The backbone
of the peptide is shown in green, and side chains are colored as
follows: Phe, Tyr, Val, Pro and Cys in yellow; Arg and His in
blue; Glu in red and Ser in magenta. Note that the side chains of
Phe56 and His67 of the bound NFKB peptide are disordered in
solution. (Figure generated with the program GRASP 183].)
respectively, which corresponds to a decrease in the cal-
culated SFE of folding of 6.2 kcal mol-1 and
6.3 kcal mol-1, respectively. Indeed, 58% of the surface of
the NFKB peptide in contact with hTRX is buried com-
pared with 6% for the free peptide (in the same confor-
mation as in the complex). Thus, the geometric and
chemical characteristics of the hTRX-NFKB peptide
interface are similar to those of other high-affinity pro-
tein-peptide interactions [38-40]. We would therefore
predict that the affinity of the NFKB peptide for hTRX
could remain high even in the absence of a disulfide
Table 2. Atomic root mean square differences.
Backbone All All ordered
atoms atoms atomsb
<SA> versus SAa 0.21 ±0.02 0.57+0.03 0.34+0.03
<SA> versus (SA) r 0.097 0.33 0.20
(SA), versus SA 0.23+0.02 0.65+0.04 0.40±0.03
aThe notation of the structures is given in the footnote of Table 1. bThe
atoms that do not exhibit conformational disorder comprise all N, Ca,
C, O and Cp atoms of residues 1-105 of hTRX and 57-67 of the NKKB
peptide; the complete hTRX side chains of residues 2, 5, 7-9, 10, 11,
14, 15, 17-19, 22-25, 27, 29-35, 38, 40-43, 45, 46, 49-55, 57, 59,
60, 62, 65-67, 69, 71, 73-80, 83, 86-92, 97 and 99-105; the complete
side chains of the NFKB peptide excluding those of residues 56 and 67;
and the hTRX side chains of M1, Q12, 528, M37, S44 and E88 up to
Cp, K3, E6, E13, D16, D20, D26, E47, D58, D61, D64, K72, Q84, N93,
K94, E95 and E98 up to Cy, and Q4, K8, K21, K36, K39, K48, E56, E68,
E70, K81, K85 and K96 up to C6.
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Fig. 4. Interactions between the NFKB
peptide and hTRX. Only residues 57-65
of the NFKB peptide, which are in con-
tact with hTRX, are shown, and the
residues of the peptide and hTRX are
depicted by lower-case and upper-case
letters, respectively. (a) Stereoview of
the backbone (N, Ca, C) of hTRX (blue)
and the NFKB peptide (red). The side
chains of hTRX and the NFKB peptide at
the interface of the complex are shown
in pink and green, respectively, and the
disulfide bond between Cys32 of hTRX
and Cys62 of the NFKB peptide is shown
in yellow. (Figure generated with the
program VISP [84].) (b) Schematic repre-
sentation of the hTRX-NFKB peptide
complex. Residues of hTRX involved in
hydrophobic interactions with the pep-
tide are shown circled, and the dashed
lines indicate hydrogen bonds, salt
bridges or electrostatic interactions. (The
NFKB peptide chain was generated by
the program MOLSCRIPT [85].)
bridge (for example if either Cys32 or S(Cys62) were
mutated to alanine).
Following attack on the Cys32-SO(Cys62) disulfide
bridge by the Cys35 thiolate anion (which, judging from
the position of Ala35 in the present structure, would be
positioned directly on top of the disulfide bridge) and the
subsequent formation of an intramolecular Cys32-Cys35
disulfide bond, it is clear that the affinity of the peptide
for thioredoxin would have to be much reduced to per-
mit its release. We suggest that this is accomplished as fol-
lows: formation of the intramolecular disulfide bridge
will necessarily alter the positioning of the S(Cys62)
residue to avoid steric clash with the Cys32-Cys35
intramolecular disulfide bridge. This in turn is likely to
disrupt the backbone hydrogen bonds involving the S_1
and S+1 residues, thereby reducing the affinity of the
peptide for oxidized hTRX. In this regard, it is interest-
ing to note that the aperture of the cleft formed by the
active site and the two opposing loops (residues 74-76
and 90-92) as measured by the Cot-Co distances
between Cys/Ala35, Pro75 and Ala92 is 10-20% wider
in the oxidized protein than in the complex. We should
also note that in the intact system, NFKB itself may
undergo a conformational change upon reduction that
facilitates its release.
Specificity requirements of hTRX
The structure of the hTRX-NFKB peptide complex
provides insight into the specificity requirements of
hTRX for its target disulfide bonds in proteins. The
identity of the S_1 residue is unlikely to influence binding
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as its side chain is directed into the solvent and only
makes contact with hTRX up to the level of the 3-car-
bon. All the remaining side chains, however, from S_5 to
S_2 and from S+l to S+3, play a role in stabilizing the
encounter complex through non-covalent interactions.
The S 5 residue should be positively charged (arginine or
lysine) to permit interaction with the carboxylates of
Asp58 and Asp61l. The' S 3 residue should have a long
hydrophobic side chain together with a functional group
to permit hydrogen bonding to the side chains of Gln63
and/or Ser67 (for example, arginine, lysine or gluta-
mine). The side chains of the S_4 and S+3 residues should
either be hydrophobic (aromatic, leucine, isoleucine,
valine or methionine) or have a long hydrophobic com-
ponent (arginine, lysine). The S2 residue should be
hydrophobic (aromatic, leucine, isoleucine, valine or
methionine) as it is buried deep within the interface of
the complex. The S+, residue should be hydrophilic and
capable of interacting with Ser90 (for example, gluta-
mate, glutamine, arginine or lysine). Finally, the S+2
residue should be small and hydrophobic to prevent steric
clashes (glycine or alanine).
It is interesting to note that the S_5 to S3 sequence of
the p50 subunit is highly preserved in the
NFKB/Rel/Dorsal transcription factor family which
includes p50, p49, p65, Rel, I-Rel and Dorsal [41,42].
The S residue is conserved in all members of the fam-
ily with the exception of I-Rel where arginine is
replaced by proline; the S4, S3, S_2, S+ 1 and S+2
residues are identical in all members of the family, and
the S+3 residue is either proline or arginine. As
expected, the S_ 1 residue is highly variable as its side
chain is fully exposed to solvent. Thus, it seems highly
likely that hTRX interacts with and activates all mem-
bers of this family by specifically reducing the disulfide
bond involving the cysteine that is homologous to
Cys62 in p50. In contrast, the sequence surrounding the
redox-sensitive cysteine in Fos and Jun, which make up
the heterodimeric AP-1 transcription factor complex, is
entirely different [43]. It is therefore not surprising to
find that hTRX alone cannot activate AP-1 DNA bind-
ing via cysteine reduction [43].
Biological implications
The activation of a growing number of transcrip-
tion factors, including NFKB, other members of
the Dorsal/Rel family, AP-1, TFIIIC, BZLF1,
Myb and p53, is regulated by a thiol-redox control
mechanism involving the reduction of a specific
cysteine residue by a cellular redox protein. In
some cases, such as that of NFKB, the cellular
redox protein is human thioredoxin (hTRX) [1-3];
in others, such as AP-1, it is a protein known as
Ref-1 [43]. An understanding of the molecular
basis of this phenomenon requires the determina-
tion of the structures of the cellular redox proteins
with their target sites on the various transcription
factors.
Activation of the DNA-binding properties of
NFKB requires that the cysteine at position 62 of
the p50 subunit be reduced [1-3]. The role of
Cys62 is readily appreciated in the light of the
recently solved crystal structure of a p50 homo-
dimer-DNA complex [28,29] which was reported
after our studies were completed. Specifically, the
p50 homodimer envelopes the DNA, locking it
into a channel. The back of the channel is closed
off by the C-terminal dimerization domain of
p50, while the front is closed off by two loops,
known as L1, one from each subunit. Cys62 is
located in the L1 loop. If Cys62 of one subunit is
disulfide bridged to Cys62 of the other in uncom-
plexed NFKB, the DNA can no longer gain access
to its binding surface on the p50 homodimer.
Likewise, if this disulfide bridge is present in the
p50 homodimer-DNA complex, the DNA can no
longer be released from the complex.
To understand how hTRX specifically recognizes
the L1 loop containing Cys62, we have deter-
mined the structure of a mixed disulfide interme-
diate complex of hTRX with a 13-residue peptide
comprising residues 56-68 of the p50 subunit of
NFKB. The structure reveals that, in addition to
the intermolecular disulfide bridge between Cys32
of hTRX and Cys62 of the NFKB peptide, the
complex is stabilized by numerous hydrogen
bonding, electrostatic and van der Waals interac-
tions involving residues S_s to S+3 (where the So
position represents the disulfide-bonded cysteine,
Cys62). Interestingly, the S(Arg57), S_ 3(Arg59),
S_2(Tyr60), So(Cys62) and S+1(Glu63) residues con-
tact the DNA in the p50 homodimer-DNA com-
plex [28,29]. Hence, these residues contribute not
only to the specificity of the interaction with
hTRX but also to that with DNA. Analysis of
these interactions permits one to define the speci-
ficity of hTRX-catalyzed disulfide bond reduc-
tion. Specifically, the S_5 residue should be
positively charged, the S_3 residue should have a
long hydrophobic side chain together with a polar
functional group, the side chains of the S_4 and
S+3 residues should be hydrophobic or have a long
hydrophobic component, the S_2 residue should
be hydrophobic, the S+1 residue should be hydro-
philic, and finally the S+2 residue should be small
and hydrophobic.
Materials and methods
Sample preparation
The [C35A, C62A, C69A, C73A] mutant of hTRX was con-
structed using mutagenic oligonucleotides in conjunction with
polymerase chain reaction (PCR) technology [44]. All cloning
procedures followed standard protocols [45]. The coding
sequence was verified by DNA sequencing [46]. Expression
and purification of the mutant hTRX was performed by pro-
cedures identical to those used previously for the wild-type and
[C62A, C69A, C73A] mutant proteins [36,47], and uniform
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labeling with either 5N or with 15N and 13C was carried out
by growing the bacteria in minimal medium with 15NH4Cl or
both 5 NH4CI and 13C6-glucose as the sole nitrogen and car-
bon sources, respectively. It is worth noting that the activity of
the triple Cys->Ala mutant protein [C62A, C69A, C73A] in
the spectrophotometric insulin reduction assay [48] is the same
as that of the wild-type protein [47]. The NFKB peptide
F5 6RFRYVCEGPSHG 6 8 was synthesized using solid-phase
methods [49] and purified by HPLC using a C4 reversed-phase
column. Purity of the peptide was checked by mass spectrome-
try and NMR spectroscopy. The complex between hTRX and
the NFKB peptide was prepared by stirring a reaction mixture
containing 0.5 mM hTRX, 1 mM NFKB peptide, 0.016 M
cysteamine, 0.009 M cystamine, 94 mM Tris-HC1, pH 8 for
4 h at room temperature, after which time 90% of the hTRX
was found to form a mixed disulfide intermediate based on
non-reducing SDS-polyacrylamide gel electrophoresis. The
complex was then purified on a C4 reversed-phase HPLC col-
umn with a 20-70% acetonitrile gradient over 40 min in 0.05%
aqueous trifluoroacetic acid. The purified complex was taken
up in either 99.996% D20 or 90% H20/10% D20 in 10 mM
sodium phosphate pH 4.4.
NMR spectroscopy
All NMR experiments were carried out at 250C on either a
Bruker AMX600 or AMX500 spectrometer equipped with a
z-shielded gradient triple resonance probe. The NMR spectra
were processed with the NmrPipe package [50], and displayed
and analyzed using the programs PIPP, CAPP and STAPP
[51]. The sequential assignment of the H, 13C and 5 N chemi-
cal shifts, stereoassignments of -methylene protons and
methyl protons of leucine and valine, and the measurement of
homonuclear and heteronuclear three-bond coupling constants
(3JHN., 3Ji 3, 3JNHP, 3JCOHP, 3JCyN, 3JCyco, 3JCC) were
achieved using the same set of 2D and 3D heteronuclear
experiments previously used in our study of reduced and oxi-
dized hTRX [32]. (Details of these double and triple resonance
experiments and original references are provided in reviews
[52-54].) The H resonances of the NFKB peptide were
assigned by means of the conventional sequential assignment
procedure [55,56] using 2D 12 C-filtered HOHAHA [57] and
12C(F1,F2)-filtered NOE spectra in D20, and 14N/ 12C(F1,F2 )-
filtered NOE and 14 N(F2)-filtered COSY spectra in H20 [58].
Approximate interproton distance restraints were derived from
the following NOE spectra recorded with a mixing time of
120 ms: 2D 12C(F 1,F2)-filtered, 12C/ 14N(F 1,F 2)-filtered, and
I4N(F2)-filtered NOE spectra [59]; 3D 15N-edited [60,61],
13 C-edited [62,63], and 13C-edited(F2)/12C-filtered(F 3) [64,65]
NOE spectra; and 4D 'lN/13 C-edited [66] 13 C/ 13C-edited
[67,68] NOE spectra. The interproton distance restraints were
grouped into four ranges, 1.8-2.7 A (1.8-2.9 A for NOEs
involving NH protons), 1.8-3.3 A (1.8-3.5 A for NOEs
involving NH protons), 1.8-5.0 A, and 1.8-6.0 A correspond-
ing to strong, medium, weak and very weak NOEs, respec-
tively [69,70]. Upper distance limits for distances involving
methyl protons and non-stereospecifically assigned methylene
protons were corrected appropriately for center averaging [71].
In addition, 0.5 A was added to the upper limit of distances
involving methyl protons to account for the higher apparent
intensity of methyl resonances [72]. Stereospecific assignments
and 4, it and xl torsion angle restraints were obtained using
the conformational grid search program STEREOSEARCH
[73] on the basis of the 3JHNa and 3JcO coupling constants and
intra-residue and sequential inter-residue interproton distance
restraints involving the NH, CoaH and C3H protons. Informa-
tion from 3JNHO and 3JCOHO coupling constants was also
employed for identifying the appropriate X1 rotamer and for
detecting rotamer averaging. X1 torsion angles for valine and
threonine residues and stereospecific assignments for the
methyl groups of valine residues were obtained from 3JCyN and
3Jcyco coupling constants, in conjunction with the pattern of
intra-residue NOEs. Finally, X2 torsion angle restraints for
isoleucine and leucine residues and stereospecific assignments
for the methyl groups of leucine were obtained from 3Jcc
coupling constants and the pattern of intra-residue NOEs [74].
Stereospecific assignments were obtained for 52 out of the
69 -methylene groups, and for all methyl groups of the 6
leucine and 11 valine residues of hTRX, and for 5 out of 10
13-methylene groups and for the methyl groups of the single
valine residue of the NFKB peptide.
Structure calculations
The structures were calculated using the hybrid distance geom-
etry-simulated annealing protocol [75] which makes use of the
program X-PLOR [76]. The target function that is minimized
during simulated annealing (SA) comprises only quadratic har-
monic potential terms for covalent geometry (that is bonds,
angles, planes and chirality), square-well quadratic potentials
for the experimental distance and torsion angle restraints, har-
monic potentials for the 3JHNa coupling constant [77,78] and
13Cot and 13C3 secondary chemical shift [79] restraints, and a
quartic van der Waals repulsion term for the non-bonded con-
tacts. No hydrogen-bonding, electrostatic or 6-12 Lennard-
Jones empirical potential energy terms are present in the target
function.
The 3JHN, coupling constants included directly in the refine-
ment comprised only those that could be measured from the
3D HNHA experiment to an accuracy of 0.5 Hz or better.
The minimum ranges employed for the 4), t4, X1 and X2 tor-
sion angle restraints were +100, +500, +200 and +200, respec-
tively [32,78]. The narrow range for some of the 4) restraints
was made possible by the availability of highly accurate 3JHNa
coupling constant data. The X2 angles of all tyrosine and
phenylalanine aromatic rings were restrained to 90±300. In all
cases, the angular standard deviations of the torsion angles for
the ensemble of 60 final SA structures were much smaller than
the ranges employed for the corresponding torsion angle
restraints, and all the 0,qi backbone torsion angles lie within
the allowed regions of the Ramachandran plot. Only struc-
turally useful intra-residue NOEs were included in the intra-
residue interproton distance restraints. Thus, NOEs between
protons separated by two bonds or between non-stereospecifi-
cally assigned protons separated by three bonds were not incor-
porated in the restraints. Hydrogen-bonding restraints, which
account for all the slowly exchanging backbone amide protons,
were only included in the final stages of refinement. The Ca
and C13 secondary shifts restraints include all hTRX residues
with the exception of the single cysteine (Cys32), histidine
(His44) and tryptophan (Trp31) residues [79].
Simulated annealing with complete cross-validation [80] was
carried out on the final set of SA structures. For each simulated
annealing run with cross-validation, the data set was randomly
partitioned into a test set comprising -10% of the data and a
reference set. Only the latter is included in the target function
that is minimized. The test set for each SA structure was there-
fore different. The atomic rms distribution about the mean
coordinate positions remains essentially unchanged upon com-
plete cross-validation and there is no significant shift in the
atomic coordinates, that is, the difference between the mean
coordinate positions before and after complete cross-validation
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(0.11 A, 0.14 A and 0.20 A for backbone atoms, all ordered
atoms and all atoms, respectively) is smaller than the rms distri-
bution of the individual structures about the mean coordinate
positions. These results indicate the high degree of complete-
ness of the experimental restraints and provide a reliable indica-
tion of the accuracy of the structures.
The coordinates of the 60 final simulated annealing (SA) struc-
tures of hTRX-NFKB peptide complex, together with the
coordinates of the restrained minimized mean structure, (SA)r,
and the complete list of experimental NMR restraints and H,
15N, 13C assignments have been deposited in the Brookhaven
Protein Data Bank.
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